| Suggest |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > News and Society > News and Society > Second Agreement between Visile City, France and Cambodian Apsara Authority |
|
Suggest - Second Agreement between Visile City, France and Cambodian Apsara Authority
Phnom Penh: Agreement on cooperation between Cambodian Apsara Authority and Visile Public Institution, According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product France, has been held in the second time on the evening of June 2, 2006, at the Cambodian Office of t ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in he Council of Ministers, Phnom Penh. Deputy Prime Minister, His Excellency SOK An, Minister of the Off lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ce of the Council of Ministers, presided over the ceremony. This second cooperation agreement was hel here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe d in the goal of developing and preserving the Angkor compound. This agreement has three important asp d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro cts: 1- discussion cooperation within the vocation of management, preservation and the development; 2- ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc Dissemination Cambodian officials to conduct studies in Visile; and 3- Inviting experts from Visile t easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi o help Cambodia as needed. The Deputy Prime Minister SOK An addressed that the cooperation agreement nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically erewith is the priority program amongst the priority foundation which will have been implemented from and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ 2006 up to 2009. This agreement concretely stipulates the aspects to be managed within the four-year ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi uration; such as scenery [trees and jungle around the compound] management, mechanism to help tourists ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a see every part of this small compound and not to impact the environment; the good management and art dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod performance in this prohibited compound, administration over the tourist group, commercial advertiseme cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin t within the prohibited area, internet management in the preservation and development vocation. The mo tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen st important point is to smooth the facilitation in different aspects of the management and preservati t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel n of the Angkor compound. His Deputy Prime Minister SOK An addressed that: in the heyday of tourism i ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust ndustry and tourist population, management capacity is needed to maintain the environment of our resor y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products t [Angkor compound]. It is worth to address that in the first time; 2002, Visile city singed with the . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de Apsara Authority in order to preserve and develop Angkor compound. The Visile city of France is the tr elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip aditional city situated the royal palace of France’s fourteenth king, the celebrated emperor in Europe tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Access to International Finance from the UK Could be the Answer you are Looking For
|